0001479290-23-000012.txt : 20230123 0001479290-23-000012.hdr.sgml : 20230123 20230123173536 ACCESSION NUMBER: 0001479290-23-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230120 FILED AS OF DATE: 20230123 DATE AS OF CHANGE: 20230123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schilke Tobin CENTRAL INDEX KEY: 0001678984 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 23545362 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, #371 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wf-form4_167451332217569.xml FORM 4 X0306 4 2023-01-20 0 0001479290 Revance Therapeutics, Inc. RVNC 0001678984 Schilke Tobin C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 0 1 0 0 CFO Common Stock 2023-01-20 4 S 0 1000 31 D 57877 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Includes 3,716 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan. /s/ Dwight Moxie, Attorney-in-Fact 2023-01-23